FluoroPharma Inc. of Boston, a developer of molecular imaging agents for the PET market, has announced successful Phase I safety results for BFPET, a fluorine-18-labeled tracer for myocardial perfusion imaging. The imaging agent analyzes blood flow in the heart and assesses coronary artery disease in patients.